Anupam Rasayan India Ltd has revised the schedule for its mandatory open offer to acquire 26.00% of the expanded voting share capital of Bliss GVS Pharma Limited, extending the tendering period to commence on July 28, 2026, and close on August 10, 2026. The acquirer, along with its wholly-owned subsidiary Mates Visa Consultancy Private Limited designated as a person acting in concert (PAC), is offering ₹299.00 per equity share for up to 2,77,26,848 shares. This update follows the receipt of final observations from the Securities and Exchange Board of India (SEBI) on July 10, 2026, and the subsequent publication of the Letter of Offer on July 18, 2026.

The Committee of Independent Directors (IDC) of Bliss GVS Pharma Limited unanimously recommended the open offer to public shareholders on July 22, 2026. While the IDC deemed the offer price of ₹299.00 fair and reasonable under the regulatory framework of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, it highlighted that the closing market prices on July 17, 2026, were significantly higher at ₹482.50 on the BSE and ₹483.50 on the NSE. The offer price was determined as the highest of the applicable pricing parameters, including the negotiated price under the Share Purchase Agreement (SPA).

Revised Schedule of Activities

The pre-offer advertisement cum corrigendum outlines key changes to the original timeline due to delays in SEBI’s feedback process. The identified date for determining eligible public shareholders remains July 14, 2026. All public shareholders, including those who acquired shares after this date or did not receive the Letter of Offer, are eligible to participate during the tendering period.

Transaction Structure and Pricing

The open offer is triggered by Anupam Rasayan’s acquisition of control over Bliss GVS Pharma through the purchase of 4,58,03,024 equity shares, representing 43.11% of the target company’s capital. Under the SPA, Anupam Rasayan assigned its right to acquire these shares to Mates Visa Consultancy Private Limited, which executed a Deed of Adherence on July 17, 2026. Consequently, all shares validly tendered in the open offer will be acquired by the PAC.

The offer is not conditional upon any minimum level of acceptance. SBI Capital Markets Limited serves as the manager to the open offer, while MUFG Intime India Private Limited acts as the registrar. The total fully paid-up share capital of Bliss GVS Pharma stands at ₹10,62,43,972, divided into 10,62,43,972 equity shares of ₹1 each. No partly paid-up shares, outstanding convertible securities (other than employee stock options), or warrants exist as of the Letter of Offer date.

Analytical Observation: Market Premium vs. Offer Price

A critical aspect of this transaction is the significant discount of the offer price relative to recent market trading levels. The volume-weighted average price on the NSE over the 60 days preceding the public announcement was ₹247.55, which formed the baseline for the regulatory pricing floor. However, the market price surged to approximately ₹483 by mid-July, creating a premium of roughly 62% over the ₹299 offer price. This divergence suggests that market participants may have priced in synergies or future prospects not reflected in the statutory offer valuation. Public shareholders must weigh the certainty of the cash exit against the potential upside of holding shares in a controlled entity, particularly given the IDC’s explicit warning about the higher market prices.

Anupam Rasayan India Ltd has signed a non-binding Letter of Intent (LOI) with BASQUEVOLT, S.A., a European developer of solid-state lithium batteries, for the potential long-term supply of a specialty chemical product. The agreement targets cumulative revenue of $300 million over a period of up to 10 years, contingent upon successful product development and the signing of a definitive supply agreement. This strategic move aims to expand the company's footprint in the electronic chemicals domain.

Agreement Details

The following table outlines the key parameters of the agreement between Anupam Rasayan and BASQUEVOLT, S.A.:

Strategic Significance

The LOI with BASQUEVOLT, S.A. represents a significant business development for Anupam Rasayan in the specialty chemicals space. Anand Desai, Managing Director of Anupam Rasayan, stated that the LOI reinforces the company's strategic focus on expanding in the electronic chemical domain, which is expected to be a key growth driver. The engagement underscores the company's strong R&D capabilities and its ability to meet stringent customer requirements in specialized chemical formulations.